Plasminogen Activator Inhibitor-1 Protects Endothelial Cells from FasL-Mediated Apoptosis

Cancer Cell

Volumn 14, Issue 4, 2008, Pages 324-334

  Bajou, Khalid ^a   Peng, Hongjun ^a   Laug, Walter E ^a   Maillard, Catherine ^b   Noel, Agnes ^b   Foidart, Jean M ^b   Martial, Joseph A ^b   DeClerck, Yves A ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

CELLBIO; CELLCYCLE

Indexed keywords

FAS LIGAND; PLASMIN; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL COUNT; CONTROLLED STUDY; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; MOUSE; NEUROBLASTOMA CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR VASCULARIZATION;

MUS;

EID: 53149129492     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2008.08.012     Document Type: Article

References (36)

1. Aoudjit F., and Vuori K. Engagement of the alpha2beta1 integrin inhibits Fas ligand expression and activation-induced cell death in T cells in a focal adhesion kinase-dependent manner. Blood 95 (2000) 2044-2051
2. Aoudjit F., and Vuori K. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis. J. Cell Biol. 152 (2001) 633-643
3. Bajou K., Noel A., Gerard R.D., Masson V., Brunner N., Holst-Hansen C., Skobe M., Fusenig N.E., Carmeliet P., Collen D., and Foidart J.M. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat. Med. 4 (1998) 923-928
4. Bajou K., Masson V., Gerard R.D., Schmitt P.M., Albert V., Praus M., Lund L.R., Frandsen T.L., Brunner N., Dano K., et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 152 (2001) 777-784
5. Bajou K., Maillard C., Jost M., Lijnen R.H., Gils A., Declerck P., Carmeliet P., Foidart J.M., and Noel A. Host-derived plasminogen activator inhibitor-1 (PAI-1) concentration is critical for in vivo tumoral angiogenesis and growth. Oncogene 23 (2004) 6986-6990
6. Blasi F., and Verde P. Urokinase-dependent cell surface proteolysis and cancer. Semin. Cancer Biol. 1 (1990) 117-126
7. Bouchet D., Tesson L., Menoret S., Charreau B., Mathieu P., Yagita H., Duisit G., and Anegon I. Differential sensitivity of endothelial cells of various species to apoptosis induced by gene transfer of Fas ligand: role of FLIP levels. Mol. Med. 8 (2002) 612-623
8. Bugge T.H., Kombrinck K.W., Flick M.J., Daugherty C.C., Danton M.J., and Degen J.L. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 87 (1996) 709-719
9. Cappellesso S., Thibault G., Hoarau C., Watier H., Bardos P., and Lebranchu Y. Induction of Jurkat T-cell apoptosis by Fas ligand-transfected endothelial cells. Transplant. Proc. 32 (2000) 2737-2738
10. Cardier J.E., Schulte T., Kammer H., Kwak J., and Cardier M. Fas (CD95, APO-1) antigen expression and function in murine liver endothelial cells: implications for the regulation of apoptosis in liver endothelial cells. FASEB J. 13 (1999) 1950-1960
11. Carmeliet P. Angiogenesis in health and disease. Nat. Med. 9 (2003) 653-660
12. Carmeliet P., Stassen J.M., Schoonjans L., Ream B., Van den Oord J.J., De Mol M., Mulligan R.C., and Collen D. Plasminogen activator inhibitor-1 gene-deficient mice. II. Effects on hemostasis, thrombosis, and thrombolysis. J. Clin. Invest. 92 (1993) 2756-2760
13. Chan J.C., Duszczyszyn D.A., Castellino F.J., and Ploplis V.A. Accelerated skin wound healing in plasminogen activator inhibitor-1-deficient mice. Am. J. Pathol. 159 (2001) 1681-1688
14. Chantrain C.F., Shimada H., Jodele S., Groshen S., Ye W., Shalinsky D.R., Werb Z., Coussens L.M., and DeClerck Y.A. Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Cancer Res. 64 (2004) 1675-1686
15. Chavakis E., and Dimmeler S. Regulation of endothelial cell survival and apoptosis during angiogenesis. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 887-893
16. Dano K., Behrendt N., Hoyer-Hansen G., Johnsen M., Lund L.R., Ploug M., and Romer J. Plasminogen activation and cancer. Thromb. Haemost. 93 (2005) 676-681
17. Deng G., Curriden S.A., Wang S., Rosenberg S., and Loskutoff D.J. Is plasminogen activator inhibitor-1 the molecular switch that governs urokinase receptor-mediated cell adhesion and release?. J. Cell Biol. 134 (1996) 1563-1571
18. Dimova E.Y., and Kietzmann T. Cell type-dependent regulation of the hypoxia-responsive plasminogen activator inhibitor-1 gene by upstream stimulatory factor-2. J. Biol. Chem. 281 (2006) 2999-3005
19. Foekens J.A., Look M.P., Peters H.A., van Putten W.L., Portengen H., and Klijn J.G. Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J. Natl. Cancer Inst. 87 (1995) 751-756
20. Folkman J. Angiogenesis and apoptosis. Semin. Cancer Biol. 13 (2003) 159-167
21. Ganesh S., Sier C.F., Griffioen G., Vloedgraven H.J., de Boer A., Welvaart K., van de Velde C.J., van Krieken J.H., Verheijen J.H., and Lamers C.B. Prognostic relevance of plasminogen activators and their inhibitors in colorectal cancer. Cancer Res. 54 (1994) 4065-4071
22. Ji J., Wernli M., Mielgo A., Buechner S.A., and Erb P. Fas-ligand gene silencing in basal cell carcinoma tissue with small interfering RNA. Gene Ther. 12 (2005) 678-684
23. Kortlever R.M., and Bernards R. Senescence, wound healing and cancer: the PAI-1 connection. Cell Cycle 5 (2006) 2697-2703
24. Luttun A., Lupu F., Storkebaum E., Hoylaerts M.F., Moons L., Crawley J., Bono F., Poole A.R., Tipping P., Herbert J.M., et al. Lack of plasminogen activator inhibitor-1 promotes growth and abnormal matrix remodeling of advanced atherosclerotic plaques in apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 499-505
25. Mitsiades N., Yu W.H., Poulaki V., Tsokos M., and Stamenkovic I. Matrix metalloproteinase-7-mediated cleavage of Fas ligand protects tumor cells from chemotherapeutic drug cytotoxicity. Cancer Res. 61 (2001) 577-581
26. Mogi M., Fukuo K., Yang J., Suhara T., and Ogihara T. Hypoxia stimulates release of the soluble form of fas ligand that inhibits endothelial cell apoptosis. Lab. Invest. 81 (2001) 177-184
27. Nagase H., Enghild J.J., Suzuki K., and Salvesen G. Stepwise activation mechanisms of the precursor of matrix metalloproteinase 3 (stromelysin) by proteinases and (4-aminophenyl)mercuric acetate. Biochemistry 29 (1990) 5783-5789
28. Nykjaer A., Conese M., Christensen E.I., Olson D., Cremona O., Gliemann J., and Blasi F. Recycling of the urokinase receptor upon internalization of the uPA:serpin complexes. EMBO J. 16 (1997) 2610-2620
29. Pepper M.S. Role of the matrix metalloproteinase and plasminogen activator-plasmin systems in angiogenesis. Arterioscler. Thromb. Vasc. Biol. 21 (2001) 1104-1117
30. Powell W.C., Fingleton B., Wilson C.L., Boothby M., and Matrisian L.M. The metalloproteinase matrilysin proteolytically generates active soluble Fas ligand and potentiates epithelial cell apoptosis. Curr. Biol. 9 (1999) 1441-1447
31. Ramos-DeSimone N., Hahn-Dantona E., Sipley J., Nagase H., French D.L., and Quigley J.P. Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J. Biol. Chem. 274 (1999) 13066-13076
32. Sata M., and Walsh K. TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat. Med. 4 (1998) 415-420
33. Sugiura Y., Ma L.Q., Sun B., Shimada H., Laug W.E., Seeger R.C., and DeClerck Y.A. The plasminogen-plasminogen activator (PA) system in neuroblastoma: role of PA inhibitor-1 in metastasis. Cancer Res. 59 (1999) 1327-1336
34. Tanaka M., Suda T., Takahashi T., and Nagata S. Expression of the functional soluble form of human fas ligand in activated lymphocytes. EMBO J. 14 (1995) 1129-1135
35. Vargo-Gogola T., Crawford H.C., Fingleton B., and Matrisian L.M. Identification of novel matrix metalloproteinase-7 (matrilysin) cleavage sites in murine and human Fas ligand. Arch. Biochem. Biophys. 408 (2002) 155-161
36. Volpert O.V., Zaichuk T., Zhou W., Reiher F., Ferguson T.A., Stuart P.M., Amin M., and Bouck N.P. Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. 8 (2002) 349-357